Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) announced that Co-founder and Chief Scientific Officer, Christopher Kirk, will join the panel discussion on "Novel Targets for Autoimmune Diseases" at William Blair's Biotech Focus Conference on July 15, 2021, at 11:00 a.m. ET. The event will be webcast live, accessible through the Events & Presentations section of Kezar's website, with a replay available for 90 days post-conference. Kezar focuses on innovative treatments for autoimmune diseases and cancer, including KZR-616, currently in Phase 2 trials for lupus nephritis and other conditions.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the “Novel Targets for Autoimmune Diseases” panel discussion at William Blair's Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET.

A live webcast of the panel may be accessed at the “Events & Presentations” section of Kezar’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005060/en/

FAQ

What is the date and time of the Kezar Life Sciences conference panel discussion?

The panel discussion is scheduled for July 15, 2021, at 11:00 a.m. ET.

Who from Kezar Life Sciences is participating in the panel discussion?

Christopher Kirk, Co-founder and Chief Scientific Officer of Kezar Life Sciences, will participate.

How can I access the webcast of the Kezar Life Sciences panel?

The live webcast can be accessed at the Events & Presentations section of Kezar's website.

What is the lead development candidate of Kezar Life Sciences?

KZR-616 is the lead development candidate, a selective immunoproteasome inhibitor.

In which conditions is KZR-616 being evaluated?

KZR-616 is being evaluated in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis.